orbusneich
透过微创经导管治疗提升患者生活质素 香港, 2024年4月24日 - (亚太商讯) - 专营经皮冠状...
ACN Newswire (简体中文)
透過微創經導管治療提升患者生活質素 香港, 2024年4月24日 - (亞太商訊) - 專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天公佈,其合資企業業聚培福有限公司(「業聚培福」)旗下用作治療血流動力學相關的三尖瓣功能不全和腔靜脈回流的產品——TricValve經導管雙腔靜脈瓣膜系統(「TricValve」),已於2024年4月22日在中國內地展開臨床試驗。 TricValve已獲得CE標誌,並分別獲美國食品藥物管理局(FDA)及國家藥品監督管理局(NMPA)授予「突破性器械(Breakthrough Device)」及「創新醫療器械」稱號。隨著該產品已為一名56歲的嚴重三尖瓣反流患者提供有效治療,標誌著產品在中國內地的臨床研究正式啟動。 是次臨床試驗由主要研究者、復旦大學附屬中山醫院葛均波院士及其團隊領導,旨在評估TricValve的安全性及有效性。葛院士亦親自為患者進行了植入手術。中山醫院是13家參與是次臨床試驗的醫療機構之一,其專家團隊認為,這款突破性療法有望徹底改變患者的治療選擇,並為患者帶來新的希望及更佳治療效果。 業聚培福總經理白志驄先生表示:「我們欣然見證TricValve臨床試驗正式展開,並實現了由中國內地心臟病專家成功植入經皮導管裝置以...
ACN Newswire (正體中文)
Enhances Patients' Quality of Life with Minimally Invasive Transcatheter Therapy HONG KONG, Apr 24, 2024 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, announced today that the Group’s joint venture OrbusNeich P+F Company Limited (“ON P&F”) has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System (“TricValve”), to treat...
ACN Newswire
Strategic M&A Initiatives Boost Product Portfolio and Market PenetrationReinforcing Business Pillars for Future Growth HONG KONG, Mar 7, 2024 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced its annual results for the year ended December 31, 2023, reporting record high revenue and net profit despite facing global economic headwinds. R...
ACN Newswire
Strengthens Global Direct Sales Team to Capture New Business Opportunities in Indonesia's Medical Industry HONG KONG, Nov 27, 2023 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, is pleased to announce that it has acquired 84% of the issued share capital of PT Revass Utama Medika ("PT Revass"), through its wholly-owned subsidiary on 27 November 2023...
ACN Newswire
HONG KONG, Nov 23, 2023 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced the acquisition of 100% interest in Eucatech AG, a German company principally engaged in the development, manufacture, and sale of minimally invasive cardiovascular and endovascular projects, for EUR2,400,000. Upon completion of the acquisition, Eucatech AG will ...
ACN Newswire
Captures Tremendous Market Opportunities through Innovation, Market Expansion, Production Line Diversification and Capacity Ramp-up HONG KONG, Aug 17, 2023 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced its interim results for the six months ended 30 June 2023, reporting growth in both revenue and net profit. Results Highlights:-- R...
ACN Newswire
HONG KONG, Dec 23, 2022 - (ACN Newswire) - Shares of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX"), under the stock code 6929. About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specialized in interventional instruments for percutaneous...
ACN Newswire
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら